BB Biotech AG : Postview of Q3 results; cutting our 2018e estimates to reflect weak start in Q4
>Q3 2018 results: Net profit of CHF 242m (Q3 2017: CHF 365m) - BB Biotech (BION) published its Q3/9M 2018 figures on 19 October, which were without surprises. Q3 net profit came in at CHF 242m (Q3 2017: CHF 365m). The total share return in Q3 2018 was 7.8% in CHF, 9.4% in EUR, and 8.8% in USD. BB Biotech was 109% invested at the end of the third quarter –stable vs H1 2018 in absolute and relative terms, but well above the 102.5% mark at the beginning of the year....Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.